
到 2028 年亚太地区中型制药市场预测 – COVID-19 影响和区域分析 – 按类型(处方药和非处方药)、药物开发类型(内部和外包)、配方(片剂和制剂)胶囊、注射剂、喷雾剂和其他制剂)和治疗类别(心血管疾病、疼痛管理、糖尿病、癌症和其他疾病)
No. of Pages: 146 | Report Code: BMIRE00026172 | Category: Life Sciences
No. of Pages: 146 | Report Code: BMIRE00026172 | Category: Life Sciences
亚太地区中型制药市场预计将从2022年的131,119.99百万美元增长到2028年的196,114.51百万美元;预计 2022 年至 2028 年复合年增长率为 6.9%。
在过去十年中,制药行业行业见证了许多变革趋势和创新,这些趋势和创新将改善该地区患者可获得的药物。在短短十年内,人工智能和大数据对疾病诊断和治疗的影响,以及从预防危及生命的疾病而不是药物治疗的转变,导致了医疗保健的发展。随着最新技术的发展,新进入者创办了多家健康初创企业。例如,酶开发和生产专家 Christopher Benoit 于 2018 年创立了 Alpha zyme。2020 年 10 月,Alp zyme 与 Qualio 合作,促进公司发展。
与大型制药公司不同,中型制药公司通常不会受到巨额管理费用和官僚机构的限制。然而,这些公司专注于药物开发的特定领域。近年来,制药公司和数字健康公司之间的合作伙伴关系显着增加。这些商业部署交易的目标是数字化医药产品、创建新公司或数十亿美元的收购。因此,制药公司在数字健康热潮中扮演着越来越重要的角色。因此,医疗保健初创企业数量的增加预计将为未来几年亚太中型制药市场的增长提供利润丰厚的增长机会。
通过引入新功能和技术,亚太中型制药市场的供应商可以吸引新客户并扩大其在新兴市场的足迹。这一因素可能会在预测期内推动市场以良好的复合年增长率增长。
亚太中型制药
2028年市场收入及预测(百万美元)
strong>
亚太地区中部规模制药市场细分
亚太地区中型制药市场按类型、药物开发类型、剂型、治疗类别和国家/地区的基础。
基于类型,亚太中型制药公司市场分为处方药和非处方药。 2022年,场外交易领域占据更大的市场份额。根据药物开发类型,市场分为内部和外包。 2022年,外包细分市场占据了更大的市场份额。根据剂型,亚太中型药品市场分为片剂和胶囊、注射剂、喷雾剂和其他剂型。平板电脑和胶囊细分市场在 2022 年占据最大的市场份额。根据治疗类别,市场分为心血管疾病、疼痛管理、糖尿病、癌症和其他疾病。 2022 年,糖尿病细分市场占据最大的市场份额。按国家/地区划分,亚太地区中型制药市场分为澳大利亚、中国、印度、日本、韩国和亚太地区其他地区。 2022 年,中国占据最大市场份额。
Alexion Pharmaceuticals, Inc.;博士健康公司;第一三共有限公司;卫材有限公司;远藤制药公司;马林克罗特;再生元制药公司;和 Sun Pharmaceutical Industries Ltd 是该地区中型制药市场的领先公司之一。
Strategic insights for Asia Pacific Mid-Size Pharmaceutical involve closely monitoring industry trends, consumer behaviours, and competitor actions to identify opportunities for growth. By leveraging data analytics, businesses can anticipate market shifts and make informed decisions that align with evolving customer needs. Understanding these dynamics helps companies adjust their strategies proactively, enhance customer engagement, and strengthen their competitive edge. Building strong relationships with stakeholders and staying agile in response to changes ensures long-term success in any market.
Report Attribute | Details |
---|---|
Market size in 2022 | US$ 131,119.99 Million |
Market Size by 2028 | US$ 196,114.51 Million |
Global CAGR (2022 - 2028) | 6.9% |
Historical Data | 2020-2021 |
Forecast period | 2023-2028 |
Segments Covered |
By 类型
|
Regions and Countries Covered | 亚太地区
|
Market leaders and key company profiles |
The regional scope of Asia Pacific Mid-Size Pharmaceutical refers to the geographical area in which a business operates and competes. Understanding regional nuances, such as local consumer preferences, economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved regions or adapting their offerings to meet regional demands. A clear regional focus allows for more effective resource allocation, targeted marketing, and better positioning against local competitors, ultimately driving growth in those specific areas.
The Asia Pacific Mid-Size Pharmaceutical Market is valued at US$ 131,119.99 Million in 2022, it is projected to reach US$ 196,114.51 Million by 2028.
As per our report Asia Pacific Mid-Size Pharmaceutical Market, the market size is valued at US$ 131,119.99 Million in 2022, projecting it to reach US$ 196,114.51 Million by 2028. This translates to a CAGR of approximately 6.9% during the forecast period.
The Asia Pacific Mid-Size Pharmaceutical Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Asia Pacific Mid-Size Pharmaceutical Market report:
The Asia Pacific Mid-Size Pharmaceutical Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The Asia Pacific Mid-Size Pharmaceutical Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the Asia Pacific Mid-Size Pharmaceutical Market value chain can benefit from the information contained in a comprehensive market report.